SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes
← catalyst calendarSponsored by Insulet Corporation (industry) · PODD — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
48actual
Sites
2
Country
New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-18 | actual | When the study began enrolling |
| Primary completion | 2025-09-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-08 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus
Intervention
- Device: Omnipod 5 SA2.0 System
Primary outcomes
what the primary-completion date above is the date OFPercentage of time in hypoglycemic range <3.9 mmol/L (<70 mg/dL) (assessed by diabetes type (type 1 and type 2))
measured End of Period 1 and Period 2 (optional) compared to Standard Therapy
Percentage of time in hyperglycemic range >13.9 mmol/L (>250 mg/dL) (assessed by diabetes type (type 1 and type 2))
measured End of Period 1 which is upto 6 weeks and Period 2 which is upto 6 months (optional) compared to Standard Therapy
Permalink · PODD's whole pipeline · Catalyst calendar · Every registered study · What changed